NEJM March 2026: Volume 394, Issue 10 – Latest Research

The March 5, 2026 issue of The Modern England Journal of Medicine features a concise report on the long-term outcomes of shunting for idiopathic normal-pressure hydrocephalus (iNPH), a condition that causes abnormal accumulation of cerebrospinal fluid in the brain’s ventricles. The study, appearing on page 1033, adds to the growing body of evidence evaluating the effectiveness of this surgical intervention, particularly in maintaining benefits over several years. INPH primarily affects older adults and can manifest as gait disturbance, cognitive decline, and urinary incontinence – symptoms that can mimic other, more common forms of dementia.

Understanding Idiopathic Normal-Pressure Hydrocephalus

Idiopathic normal-pressure hydrocephalus is, as the name suggests, characterized by normal cerebrospinal fluid (CSF) pressure despite an enlarged volume of CSF. The “idiopathic” part means the cause is often unknown, though it can sometimes be linked to prior brain injury or infection. CSF acts as a cushion for the brain and spinal cord, and also carries nutrients and removes waste products. When this fluid doesn’t drain properly, it leads to the ventricular enlargement seen in iNPH. The symptoms – difficulty walking, cognitive impairment, and bladder control issues – create a diagnostic triad, but these symptoms can overlap with other conditions, making accurate diagnosis challenging. The National Institute of Neurological Disorders and Stroke (NINDS) provides further information on this condition.

The NEJM Study: Long-Term Shunt Outcomes

The report in NEJM doesn’t present new clinical trial data, but rather a focused analysis of patients previously enrolled in larger studies evaluating shunt surgery. Shunting involves surgically implanting a tube (the shunt) to divert excess CSF from the brain to another part of the body, typically the abdominal cavity, where it can be absorbed. The study examined the durability of improvements in gait, cognition, and continence observed after shunting. While initial improvements are often seen, maintaining those benefits over time is a key concern. The authors found that while some patients experienced sustained improvement, a significant proportion saw their symptoms recur within a few years.

It’s crucial to note the study’s limitations. The analysis is retrospective, meaning it looks back at data already collected, rather than following patients forward in time. This type of study can be prone to biases, as researchers have no control over how the data were originally gathered. The study doesn’t address who benefits most from shunting. Identifying factors that predict a positive long-term response remains an area of active research.

What Does This Mean for Patients?

The findings underscore the fact that shunting for iNPH is not a cure, but rather a management strategy. While it can significantly improve symptoms for some individuals, it doesn’t guarantee lasting relief. Patients considering shunting should have a thorough evaluation to confirm the diagnosis of iNPH and to rule out other potential causes of their symptoms. This evaluation typically includes a neurological exam, brain imaging (MRI or CT scan), and sometimes a CSF tap test, where a small amount of CSF is removed to observe if symptoms temporarily improve.

The decision to proceed with shunting should be made in consultation with a neurosurgeon experienced in treating iNPH, and should involve a careful discussion of the potential benefits and risks. Patients should also understand that ongoing follow-up is essential to monitor shunt function and to address any complications that may arise. Shunt malfunction, infection, and over-drainage of CSF are potential complications that can require further intervention.

Beyond Shunting: Emerging Approaches

Research into iNPH is ongoing, and several promising new approaches are being explored. One area of interest is the development of alternative surgical techniques, such as endoscopic third ventriculostomy (ETV), which creates a small opening in the floor of the third ventricle to allow CSF to flow more freely. A recent review in Frontiers in Neurology discusses the evolving role of ETV in iNPH management. Another avenue of investigation is the use of biomarkers to identify patients who are most likely to respond to treatment. Identifying these biomarkers could help personalize treatment decisions and improve outcomes.

The Role of Zorevunersen in Neurological Disorders

Interestingly, the March 5th issue of The New England Journal of Medicine also features a separate publication detailing positive results from studies of zorevunersen, an investigational medicine for Dravet syndrome, a rare genetic neurodevelopmental disease. As reported by Pharmiweb, the data suggest zorevunersen may improve outcomes by targeting the underlying genetic cause of the disease. While Dravet syndrome is distinct from iNPH, both conditions highlight the growing potential of precision medicine in addressing neurological disorders.

What Comes Next: Refining Patient Selection and Long-Term Monitoring

The future of iNPH management lies in refining patient selection criteria and improving long-term monitoring strategies. Larger, prospective studies are needed to identify the factors that predict a favorable response to shunting, and to compare the effectiveness of different surgical techniques. Developing more reliable biomarkers would also be a significant step forward. Ongoing surveillance of shunt function and patient symptoms is crucial to ensure optimal outcomes and to address any complications promptly. The continued publication of research in journals like The New England Journal of Medicine will undoubtedly contribute to a deeper understanding of this complex condition and to the development of more effective treatments.